{"DataElement":{"publicId":"14717827","version":"1","preferredName":"Systemic Antifungal Agent Administered Type","preferredDefinition":"A description of the systemic antifungal agent that was administered.","longName":"4722981v1.00:5073212v1.00","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"4722981","version":"1","preferredName":"Systemic Antifungal Agent Administered","preferredDefinition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body._Drugs that treat infections caused by fungi._The act of having given something (e.g., a medication or test).","longName":"4722979v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"4722979","version":"1","preferredName":"Systemic Therapy Antifungal Agent","preferredDefinition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.:Drugs that treat infections caused by fungi.","longName":"C15698:C514","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systemic Therapy","conceptCode":"C15698","definition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antifungal Agent","conceptCode":"C514","definition":"Substances that treat systemic or topical infections caused by fungi. Antifungal agents kill or inhibit the growth of fungi, by various mechanisms. These mechanisms include inhibition of fungal mitosis, impairing synthesis or binding to ergosterol, inhibition of RNA or DNA synthesis, and interfering with other fungal metabolic processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FC1443D-AE86-FC99-E050-BB89AD434ED4","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-02-23","modifiedBy":"ONEDATA","dateModified":"2015-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FC1443D-AE94-FC99-E050-BB89AD434ED4","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-02-23","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5073212","version":"1","preferredName":"Antifungal Agent Type","preferredDefinition":"Drugs that treat infections caused by fungi._Something distinguishable as an identifiable class based on common qualities.","longName":"5073212v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Posaconazole","valueDescription":"Posaconazole","ValueMeaning":{"publicId":"2794973","version":"1","preferredName":"Posaconazole","longName":"2794973","preferredDefinition":"A broad-spectrum, second generation, triazole compound with antifungal activity. Posaconazole strongly inhibits 14-alpha demethylase, a cytochrome P450-dependent enzyme. Inhibition of 14-alpha-demethylase prevents the conversion of lanosterol to ergosterol, an important component of the fungal cell wall. Inhibition of ergosterol synthesis changes the fungal cell membrane composition and integrity, alters membrane permeability and eventually leads to fungal cell lysis. Compared to other azole antifungals, posaconazole is a significantly more potent inhibitor of sterol 14-alpha demethylase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Posaconazole","conceptCode":"C61500","definition":"A broad-spectrum, second generation, triazole compound with antifungal activity. Posaconazole strongly inhibits 14-alpha demethylase, a cytochrome P450-dependent enzyme. Inhibition of 14-alpha-demethylase prevents the conversion of lanosterol to ergosterol, an important component of the fungal cell wall. Inhibition of ergosterol synthesis changes the fungal cell membrane composition and integrity, alters membrane permeability and eventually leads to fungal cell lysis. Compared to other azole antifungals, posaconazole is a significantly more potent inhibitor of sterol 14-alpha demethylase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A01A143-F070-52D0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"261938BC-025F-DBF7-E050-BB89AD4347C5","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"Itraconazole","valueDescription":"Itraconazole","ValueMeaning":{"publicId":"2578206","version":"1","preferredName":"Itraconazole","longName":"2578206","preferredDefinition":"A synthetic triazole agent with antimycotic properties. Formulated for both topical and systemic use, itraconazole preferentially inhibits fugal cytochrome P450 enzymes, resulting in a decrease in fungal ergosterol synthesis.  Because of its low toxicity profile, this agent can be used for long-term maintenance treatment of chronic fungal infections. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Itraconazole","conceptCode":"C1138","definition":"A synthetic triazole agent with antimycotic properties. Formulated for both topical and systemic use, itraconazole preferentially inhibits fungal cytochrome P450 enzymes, resulting in a decrease in fungal ergosterol synthesis.  Because of its low toxicity profile, this agent can be used for long-term maintenance treatment of chronic fungal infections. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE8B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"261938BC-0269-DBF7-E050-BB89AD4347C5","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"Fluconazole","valueDescription":"Fluconazole","ValueMeaning":{"publicId":"2576944","version":"1","preferredName":"Fluconazole","longName":"2576944","preferredDefinition":"A synthetic triazole with antifungal activity. Fluconazole preferentially inhibits fungal cytochrome P-450 sterol C-14 alpha-demethylation, resulting in the accumulation of fungal 14 alpha-methyl sterols, the loss of normal fungal sterols, and fungistatic activity. Mammalian cell demethylation is much less sensitive to fluconazole inhibition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluconazole","conceptCode":"C500","definition":"A synthetic triazole with antifungal activity. Fluconazole preferentially inhibits fungal cytochrome P-450 sterol C-14 alpha-demethylation, resulting in the accumulation of fungal 14 alpha-methyl sterols, the loss of normal fungal sterols, and fungistatic activity. Mammalian cell demethylation is much less sensitive to fluconazole inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F99D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"261938BC-0273-DBF7-E050-BB89AD4347C5","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"Caspofungin","valueDescription":"Caspofungin","ValueMeaning":{"publicId":"2577795","version":"1","preferredName":"Caspofungin","longName":"2577795","preferredDefinition":"The acetate salt of an antimycotic echinocandin lipopeptide, semisynthetically derived from a fermentation product of the fungus Glarea lozoyensis. Caspofungin inhibits 1,3-beta-glucan synthase, resulting in decreased synthesis of beta(1,3)-D-glucan (an essential component of the fungal cell wall), weakening of the fungal cell wall, and fungal cell wall rupture. This agent is active against Aspergillus and Candida species.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Caspofungin","conceptCode":"C28910","definition":"An antimycotic echinocandin lipopeptide, semisynthetically derived from a fermentation product of the fungus Glarea lozoyensis. Caspofungin inhibits 1,3-beta-glucan synthase, resulting in decreased synthesis of beta(1,3)-D-glucan (an essential component of the fungal cell wall), weakening of the fungal cell wall, and fungal cell wall rupture. This agent is active against Aspergillus and Candida species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"261938BC-02A8-DBF7-E050-BB89AD4347C5","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"Isavuconazole","valueDescription":"Isavuconazole","ValueMeaning":{"publicId":"5073216","version":"1","preferredName":"Isavuconazole","longName":"5073216","preferredDefinition":"A water-soluble triazole prodrug with broad-spectrum antifungal activity. Isavuconazole is absorbed easily, given either orally or intravenously, and is hydrolyzed to its active moiety BAL4815 by plasma esterases. BAL4815 inhibits fungal cytochrome P450 lanosterol 14-alpha-demethylase (CYP51) that catalyzes the conversion of lanosterol to ergosterol, an important component of the fungal cell membrane. Enzyme inhibition by this agent leads to a decrease in ergosterol pool and therefore disturbs synthesis of fungal cell membrane, thereby increasing cell membrane permeability and promoting loss of essential intracellular elements. This ultimately causes fungal cell lysis and death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Isavuconazole","conceptCode":"C64543","definition":"A water-soluble triazole prodrug with broad-spectrum antifungal activity. Isavuconazole is absorbed easily, given either orally or intravenously, and is hydrolyzed to its active moiety BAL4815 by plasma esterases. BAL4815 inhibits fungal cytochrome P450 lanosterol 14-alpha-demethylase (CYP51) that catalyzes the conversion of lanosterol to ergosterol, an important component of the fungal cell membrane. Enzyme inhibition by this agent leads to a decrease in ergosterol pool and therefore disturbs synthesis of fungal cell membrane, thereby increasing cell membrane permeability and promoting loss of essential intracellular elements. This ultimately causes fungal cell lysis and death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"261938BC-02B2-DBF7-E050-BB89AD4347C5","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"261938BC-02CB-DBF7-E050-BB89AD4347C5","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"Voriconazole","valueDescription":"Voriconazole","ValueMeaning":{"publicId":"2575726","version":"1","preferredName":"Voriconazole","longName":"2575726","preferredDefinition":"A synthetic triazole with antifungal activity. Voriconazole selectively inhibits 14-alpha-lanosterol demethylation in fungi, preventing the production of ergosterol, an essential constituent of the fungal cell membrane, and resulting in fungal cell lysis. (NCI04).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Voriconazole","conceptCode":"C1707","definition":"A synthetic triazole with antifungal activity. Voriconazole selectively inhibits 14-alpha-lanosterol demethylation in fungi, preventing the production of ergosterol, an essential constituent of the fungal cell membrane, and resulting in fungal cell lysis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"COOPERM","dateModified":"2017-05-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"261938BC-02D5-DBF7-E050-BB89AD4347C5","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"None","valueDescription":"None","ValueMeaning":{"publicId":"2577064","version":"1","preferredName":"None","longName":"2577064","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA15-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"261938BC-02E0-DBF7-E050-BB89AD4347C5","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"Other antifungal drug","valueDescription":"Other Antifungal Agent","ValueMeaning":{"publicId":"5073217","version":"1","preferredName":"Other Antifungal Agent","longName":"5073217","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Drugs that treat infections caused by fungi.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antifungal Agent","conceptCode":"C514","definition":"Substances that treat systemic or topical infections caused by fungi. Antifungal agents kill or inhibit the growth of fungi, by various mechanisms. These mechanisms include inhibition of fungal mitosis, impairing synthesis or binding to ergosterol, inhibition of RNA or DNA synthesis, and interfering with other fungal metabolic processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"261938BC-02ED-DBF7-E050-BB89AD4347C5","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"KUMMEROA","dateModified":"2022-07-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"261938BC-0306-DBF7-E050-BB89AD4347C5","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"Micafungin","valueDescription":"Micafungin","ValueMeaning":{"publicId":"2794943","version":"1","preferredName":"Micafungin","longName":"2794943","preferredDefinition":"A semi-synthetic echinocandin derived from a natural product of the fungus Coleophama empedri with potent antifungal activity. Micafungin, like other cyclic lipopeptides, noncompetitively inhibits the fungal specific enzyme 1,3-beta-D-glucan synthase, an enzyme essential for fungal cell wall synthesis. Inhibition of this enzyme weakens of the cell wall, thereby leading to osmotic lysis and eventually, fungal cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Micafungin","conceptCode":"C1850","definition":"A semi-synthetic echinocandin derived from a natural product of the fungus Coleophama empedri with potent antifungal activity. Micafungin, like other cyclic lipopeptides, noncompetitively inhibits the fungal specific enzyme 1,3-beta-D-glucan synthase, an enzyme essential for fungal cell wall synthesis. Inhibition of this enzyme weakens of the cell wall, thereby leading to osmotic lysis and eventually, fungal cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A00A568-3058-15CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"5.5.17  Updated concept definition to synch with current NCIt. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"261938BC-0310-DBF7-E050-BB89AD4347C5","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"Anidulafungin","valueDescription":"Anidulafungin","ValueMeaning":{"publicId":"2762697","version":"1","preferredName":"Anidulafungin","longName":"2762697","preferredDefinition":"A cyclic lipopeptide echinocandin derivative with antifungal activity.  Anidulafungin inhibits 1,3 beta-D-glucan synthase, an enzyme involved in fungal cell wall synthesis, resulting in cell lysis and death. This agent is active against Candida species and Aspergillus. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anidulafungin","conceptCode":"C38716","definition":"A cyclic lipopeptide echinocandin derivative with antifungal activity.  Anidulafungin inhibits 1,3 beta-D-glucan synthase, an enzyme involved in fungal cell wall synthesis, resulting in cell lysis and death. This agent is active against Candida species and Aspergillus. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5111047F-8F59-4420-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-07-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"261938BC-031A-DBF7-E050-BB89AD4347C5","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"Amphotericin products","valueDescription":"Amphotericin Product","ValueMeaning":{"publicId":"5081168","version":"1","preferredName":"Amphotericin Product","longName":"5081168","preferredDefinition":"Any formulation containing amphotericin B as the active agent for the treatment of fungal infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amphotericin Product","conceptCode":"C124792","definition":"Any formulation containing amphotericin B as the active agent for the treatment of fungal infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"267C06DB-4BE9-1CF6-E050-BB89AD435C94","latestVersionIndicator":"Yes","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"KUMMEROA","dateModified":"2022-07-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"267C06DB-4C02-1CF6-E050-BB89AD435C94","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"ONEDATA","dateModified":"2015-12-09","deletedIndicator":"No"},{"value":"Amphotericin B Deoxycholate","valueDescription":null,"ValueMeaning":{"publicId":"2794946","version":"1","preferredName":"Amphotericin B Deoxycholate","longName":"2794946","preferredDefinition":"The deoxycholate salt of amphotericin B, a polyene antifungal antibiotic produced by Streptomyces nodosus, with antifungal activity. Amphotericin B binds to ergosterol, an essential component of the fungal cell membrane, resulting in depolarization of the membrane; alterations in cell membrane permeability and leakage of important intracellular components; and cell rupture. This agent may also induce oxidative damage in fungal cells and has been reported to stimulate host immune cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amphotericin B Deoxycholate","conceptCode":"C62201","definition":"The deoxycholate salt of amphotericin B, a polyene antifungal antibiotic produced by Streptomyces nodosus, with antifungal activity. Amphotericin B binds to ergosterol, an essential component of the fungal cell membrane. This results in depolarization of the cell membrane, alterations in cell membrane permeability, leakage of important intracellular components, and cell rupture. This agent may also induce oxidative damage in fungal cells and has been reported to stimulate host immune cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A00A568-30F5-15CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F9E721D-03CA-0F19-E063-731AD00AC902","beginDate":"2024-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-23","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"Liposomal Amphotericin B","valueDescription":null,"ValueMeaning":{"publicId":"2576889","version":"1","preferredName":"Amphotericin B-Lipid Complex","longName":"2576889","preferredDefinition":"Consists of the macrolide antibiotic Amphotericin B complexed with dimyristoyl phosphatidylcholine and dimyristoyl phosphatidylglycerol, formulated to provide lower toxicity with efficacy similar to the parent compound, Amphotericin B.  Amphotericin B binds to ergosterol altering cell membrane integrity with subsequent cell death. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liposomal Amphotericin B","conceptCode":"C1566","definition":"A liposome-encapsulated formulation of the polyene antifungal antibiotic amphotericin B produced by the bacterium Streptomyces nodosus with antifungal activity. Amphotericin B binds to ergosterol, an essential component of the fungal cell membrane, and alters cell membrane integrity, resulting in leakage of intracellular components and cell rupture. This agent may also induce oxidative damage in fungal cells and has been reported to stimulate host immune cells. Compared to amphotericin B alone, liposomal delivery of amphotericin B allows for a greater drug concentration in target tissues while decreasing systemic side effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F966-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F9E721D-03CB-0F19-E063-731AD00AC902","beginDate":"2024-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-23","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"Ravuconazole","valueDescription":null,"ValueMeaning":{"publicId":"2794972","version":"1","preferredName":"Ravuconazole","longName":"2794972","preferredDefinition":"A triazole with antifungal activity. Ravuconazole inhibits 14a demethylase, an enzyme involved in sterol synthesis, resulting in lysis of the fungal cell wall and fungal cell death. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ravuconazole","conceptCode":"C38688","definition":"A triazole with antifungal activity. Ravuconazole inhibits 14a demethylase, an enzyme involved in sterol synthesis, resulting in lysis of the fungal cell wall and fungal cell death. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A01A143-F049-52D0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F9E721D-03CC-0F19-E063-731AD00AC902","beginDate":"2024-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-23","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5073211","version":"1","preferredName":"Antifungal Agent Type","preferredDefinition":"Drugs that treat infections caused by fungi.:Something distinguishable as an identifiable class based on common qualities.","longName":"C514:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antifungal Agent","conceptCode":"C514","definition":"Substances that treat systemic or topical infections caused by fungi. Antifungal agents kill or inhibit the growth of fungi, by various mechanisms. These mechanisms include inhibition of fungal mitosis, impairing synthesis or binding to ergosterol, inhibition of RNA or DNA synthesis, and interfering with other fungal metabolic processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"261938BC-0238-DBF7-E050-BB89AD4347C5","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"261938BC-0249-DBF7-E050-BB89AD4347C5","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What was the systemic antifungal agent administered?","url":null,"context":"NHLBI"},{"name":"NMDP Text 1","type":"Application Standard Question Text","description":"Systemic antifungal drugs","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"0F9E9697-8AC9-1540-E063-731AD00AE96B","latestVersionIndicator":"Yes","beginDate":"2024-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-23","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","changeDescription":null,"administrativeNotes":"2024.1.23 Created per ticket request CADSR0003318. ak","unresolvedIssues":null,"deletedIndicator":"No"}}